| Symbol | KTTAW |
|---|---|
| Name | PASITHEA THERAPEUTICS CORP. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1111 LINCOLN ROAD,SUITE 500, MIAMI BEACH, Florida, 33139, United States |
| Telephone | +1 786 - 977-3380 |
| Fax | — |
| — | |
| Website | https://www.pasithea.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001841330 |
| Description | Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. Additional info from NASDAQ: |
New Form ARS - Pasithea Therapeutics Corp. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001213900-26-086803 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Pasithea Therapeutics Corp. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001213900-26-086799 <b>Size:</b> 1 MB
Read moreNew Form SCHEDULE 13G/A - Pasithea Therapeutics Corp. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0001493152-26-035625 <b>Size:</b> 23 KB
Read moreNew Form PRE 14A - Pasithea Therapeutics Corp. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001213900-26-082894 <b>Size:</b> 2 MB
Read morePasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Read morePasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Read morePasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Read morePasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Read morePasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Read moreNew Form SCHEDULE 13G - Pasithea Therapeutics Corp. <b>Filed:</b> 2026-06-23 <b>AccNo:</b> 0001440771-26-000010 <b>Size:</b> 18 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | Phase1 | NF1 Mutation | Recruiting | 2025-05-30 | 2027-12-01 | ClinicalTrials.gov |
| NCT06299839 | PAS-004 in Patients With Advanced Solid Tumors | Phase1 | RAS Mutation | Recruiting | 2024-02-29 | 2027-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PAS-004 Tablets | Other | Phase PHASE1 | RAS Mutation | RECRUITING | NCT06299839 |
| PAS-004 Capsules | Other | Phase PHASE1 | RAS Mutation | RECRUITING | NCT06299839 |
| PAS-004 Tablets | Other | Phase PHASE1 | NF1 Mutation | RECRUITING | NCT06961565 |
| PAS-004 Tablets | DRUG | Phase PHASE1 | NF1 Mutation | RECRUITING | NCT06961565 |
| PAS-004 Capsules | DRUG | Phase PHASE1 | RAS Mutation | RECRUITING | NCT06299839 |